1stOncology™: Cancer Intelligence Service – Page 13232 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

VBL Therapeutics to Present at the Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women’s Cancer on March 18

On March 11, 2019 VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, reported that the company will present data on its Phase 3 candidate VB-111, at the SGO 50th Annual Meeting on Women’s Cancer, to be held March 16 – 19, 2019 at the Hawaii Convention Center in Honolulu, Hawaii (Press release, VBL Therapeutics, MAR 11, 2019, View Source [SID1234534216]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Presentation Details:

Abstract: Ofranergene Obadenovec (VB-111), an anti-cancer gene therapy, induces immunotherapeutic effect in platinum resistant ovarian cancer: histopathology findings

Session title: Poster Day 2

Date: Monday, March 18, 2019

Time: 15:30 – 17:00 PM Hawaii Standard Time

Poster #: 2028
About Ofranergene Obadenovec (VB-111)
VB-111, a potential first-in-class anticancer therapeutic candidate, is the Company’s lead oncology product currently being studied in a Phase 3 trial for ovarian cancer. VB-111 has received orphan drug designation in both the US and Europe, and fast track designation in the US for prolongation of survival in patients with rGBM. In addition, VB-111 successfully demonstrated proof-of-concept and survival benefit in Phase 2 clinical trials in radioiodine-refractory thyroid cancer and recurrent platinum-resistant ovarian cancer. VB-111 has received an Orphan Designation for the treatment of ovarian cancer by the European Medicines Agency (EMA).

About VBL

Soligenix to Present at the Boston Oncology Investor Conference 2019

On March 11, 2019 Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that its Chief Scientific Officer, Oreola Donini, PhD, will deliver a corporate presentation at the Boston Oncology Investor Conference 2019 on Thursday, March 14 at 5:35 PM ET (Press release, Soligenix, MAR 11, 2019, View Source [SID1234534209]). The event will take place at 28 State Street, Boston, MA.

To access the Soligenix corporate presentation, please visit here.

About Boston Oncology Investor Conference 2019

The Boston Oncology Investor Conference 2019 at Cowen Healthcare Week is organized by OneMed Forum, and sponsored by the National Foundation for Cancer Research, the International Cancer Impact Fund, Klosters Innovation Partners, McDermott Will & Emery, Torreya Partners, and Marcum. The event sponsor is McDermott Will & Emery. The meeting includes leading life science and oncology venture capitalists, family offices, lawyers, pharma executives, startup public and private cancer companies, and cancer foundations for a discussion of trends, opportunities, and risks in oncology investing, corporate presentations by a select group of public and private oncology companies, and updates on cutting edge science. For more information about the conference, please refer to the conference website.

Sirnaomics to Present at the 4th Annual Oligonucleotide & Precision Therapeutics: Discovery, Development and Delivery

On March 11, 2019 Sirnaomics Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, reported that the Company’s management will present its platform technology and discuss the potential utility of RNAi therapeutics at the 4th Annual Oligonucleotide & Precision Therapeutics: Discovery, Development and Delivery conference on March 25-28, 2019 in Cambridge, Massachusetts (Press release, Sirnaomics, MAR 11, 2019, View Source;precision-therapeutics-discovery-development-and-delivery-300810415.html [SID1234534208]).

Patrick Lu, PhD, President and Chief Executive Officer, will share an overview of Sirnaomics’ differentiated RNAi technology platform, which leverages a proprietary polypeptide nanoparticle (PNP) drug delivery system, and the Company’s pipeline of RNAi therapeutics spanning oncology and anti-fibrosis indications at the following presentations.

Presentation: Chairperson’s RemarksDate & Time: March 26, 10:45 am ET
Presentation Title: Novel siRNA Therapeutics for Immune Oncology TherapeuticsPresentation Track: Oligonucleotide Discovery and DeliveryDate & Time: March 26, 2 pm ET
Presentation Title: Can We Push for siRNA Cancer Therapeutics Similar to Experiences with mAbs?Date & Time: March 27, 8 am ET
Also, Dmitry Samarsky, PhD, Chief Technology Officer of Sirnaomics, will chair a short course, "Examining The Safety and Toxicity of Nucleic Acid Therapeutics", on Monday, March 25 starting at 6:50 pm ET. He will also participate in a panel discussion, "Bridging the Gap between Discovery, Development and Compliance", on Tuesday, March 26 at 9:15 am ET.

LABCORP’S ZERO COUPON CONVERTIBLE SUBORDINATED NOTES DUE 2021 TO ACCRUE CONTINGENT INTEREST

On March 11, 2019 LabCorp (NYSE: LH) reported that for the period of March 11, 2019 to Sept. 10, 2019, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will accrue (subject to the terms of the Zero Coupon Notes) contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 6, 2019, in addition to the continued accrual of the original issue discount (Press release, LabCorp, MAR 11, 2019, View Source [SID1234534204]). Contingent cash interest, which the Company has determined to be approximately $2.47 per Note, will be payable to holders of the Zero Coupon Notes as of the record date, which is Aug. 27, 2019. The payment of contingent cash interest is expected to be made on Sept. 11, 2019.

Seres Therapeutics Announces Microbiome Immuno-Oncology Focused Collaboration with AstraZeneca

On March 11, 2019 Seres Therapeutics, Inc. (Nasdaq: MCRB) reported a three-year research collaboration with AstraZeneca (Press release, Seres Therapeutics, MAR 11, 2019, View Source [SID1234534207]). The collaboration will focus on advancing mechanistic understanding of the microbiome in augmenting the efficacy of cancer immunotherapy, including potential synergy with AstraZeneca compounds.

Under the collaboration, research will evaluate microbiome-based approaches as a predictor for which patients may respond best to certain cancer immunotherapies. Additionally, SER-401, an investigational microbiome therapeutic, may be studied in combination with AstraZeneca compounds targeting various cancers. The collaboration will apply Seres’ microbiome drug discovery and manufacturing expertise with AstraZeneca’s extensive oncology experience to evaluate the potential for microbiome therapy to improve clinical response when used in conjunction with adjunctive pharmaceutical approaches.

"We are very pleased to be collaborating with AstraZeneca, a global leader in oncology, to advance the development of potential microbiome-based therapies for cancer. Through the activities under this collaboration and in our SER-401 Phase 1b clinical study in metastatic melanoma, we hope to meaningfully advance our understanding of the potential for microbiome therapeutics to magnify the impact of cancer immunotherapy," said Eric Shaff, President and Chief Executive Officer of Seres Therapeutics.

"Our new collaboration with Seres Therapeutics represents an important opportunity to advance our understanding of the relationship between the microbiome and the immune system’s ability to respond to cancer therapy," said Jean-Charles Soria, M.D., Ph.D., Senior Vice President, Research & Development Oncology at AstraZeneca. "Despite progress in the field of immunotherapy, we are only at the tip of the iceberg. Too many patients are still unable to benefit from existing therapies, so we must continue following the science in pursuit of new and innovative solutions."

Under the terms of the exclusive collaboration, AstraZeneca will provide Seres with $20 million in three equal installments over two years, with the first payment due at the start of the agreement. In addition, AstraZeneca will also reimburse Seres for research activity related to the collaboration. Seres will maintain rights to oncology targeted microbiome therapeutic candidates, and AstraZeneca will obtain the option to negotiate for rights to those programs and other inventions arising out of the collaboration.